#experimental therapies

The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats

Researchers used an airway-on-a-chip that mimics living lung tissue to screen approved drugs for use against SARS-CoV-2.

Molnupiravir, first developed for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.

None of the four drugs tested in the WHO’s Solidarity trial reduced mortality or duration of hospitalization.

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.

Sofosbuvir and daclatasvir were linked to faster recovery and improved survival in studies in Iran.

Dexamethasone reduced mortality by up to a third among severely ill patients who needed supplemental oxygen or ventilators.

FDA grants emergency use authorization, but randomized clinical trials of the antiviral drug show mixed results.

Drugs used for decades to treat malaria may help people with the new coronavirus, but clinical trials are needed.

The protease inhibitor combination did not work significantly better than supportive care, though those treated earlier might benefit.